Evidence map›Paper›PMID 27091570›Full record

Observational studyThe Journal of urology2016

Sociodemographic and Clinical Predictors of Switching to Active Treatment among a Large, Ethnically Diverse Cohort of Men with Low Risk Prostate Cancer on Observational Management.

Scott P Kelly, Stephen K Van Den Eeden, Richard M Hoffman, David S Aaronson, Tania Lobo, George Luta, Amethyst D Leimpter, Jun Shan, Arnold L Potosky, Kathryn L Taylor

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in The Journal of urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Observational
  4. Article
  5. Social Determinants of Appropriate Treatment for Muscle-Invasive Bladder Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Scott P KellyLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C.. Electronic address: spk23@georgetown.edu.
Stephen K Van Den EedenDepartment of Urology, Kaiser Oakland Medical Center, Northern California, Oakland, California.
Richard M HoffmanDepartment of Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa.
David S AaronsonDepartment of Urology, Kaiser Oakland Medical Center, Northern California, Oakland, California.
Tania LoboLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C.
George LutaLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C.
Amethyst D LeimpterDivision of Research, Kaiser Permanente Northern California, Oakland, California.
Jun ShanDivision of Research, Kaiser Permanente Northern California, Oakland, California.
Arnold L PotoskyLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C.
Kathryn L TaylorLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C.

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Christopher K Laubenthal · 2000 to 2026
$70.0M
TREATMENT DECISIONS AND PATIENT REPORTED OUTCOMES IN LOW RISK PROSTATE CANCERR01CA155578 · NCI · GEORGETOWN UNIVERSITY · PI TAYLOR, KATHRYN L, VAN DEN EEDEN, STEPHEN K. · 2011 to 2015
$3.1M
NCI NIH HHS R01 CA155578
6 · The paper itself

Abstract

purposeWe determined the clinical and sociodemographic predictors of beginning active treatment in an ethnically diverse population of men with low risk prostate cancer initially on observational treatment. MATERIALS AND

methodsWe retrospectively studied men diagnosed with low risk prostate cancer between 2004 and 2012 at Kaiser Permanente Northern California who did not receive any treatment within the first year of diagnosis and had at least 2 years of followup. We used Cox proportional hazards regression models to determine factors associated with time from diagnosis to active treatment.

resultsWe identified 2,228 eligible men who were initially on observation, of whom 27% began active treatment during followup at a median of 2.9 years. NonHispanic black men were marginally more likely to begin active treatment than nonHispanic white men independent of baseline and followup clinical measures (HR 1.3, 95% CI 1.0-1.7). Among men who remained on observation nonHispanic black men were rebiopsied within 24 months of diagnosis at a slightly lower rate than nonHispanic white men (HR 0.70, 95% CI 0.6-1.0). Gleason grade progression (HR 3.3, 95% CI 2.7-4.1) and PSA doubling time less than 48 months (HR 2.9, 95% CI 2.3-3.7) were associated with initiation of active treatment independent of race.

conclusionsSociodemographic factors such as ethnicity and education may independently influence the patient decision to pursue active treatment and serial biopsies during active surveillance. These factors are important for further studies of prostate cancer treatment decision making.

Indexed as

EthnicityNeoplasm GradingAdultAgedBiopsyCaliforniaCombined Modality TherapyDisease ProgressionFollow-Up StudiesHumansMaleMiddle AgedProstateProstatic NeoplasmsRetrospective StudiesTime FactorsAfrican Americansdisease progressionearly detection of cancerprostatic neoplasmswatchful waiting

Identifiers

PMID27091570
PMCPMC5094279

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.